Form D · Biotechnology
Vera Therapeutics, Inc.
South San Francisco, CA · CIK 0001831828
Offering snapshot reported Feb 25, 2021 · SEC filing
- Reported sold
- $70.7M Offering amount: $70.7M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 29, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 25, 2021 | Initial | $70,736,334 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-390559
Includes $5,736,335.77 in cancelled convertible debt and does not include $28,121,124.59 sold to two investors who reside outside the United States.
Source: Form D, filed Feb 25, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew Cheng | Director |
| Patrick Enright | Director |
| Marshall Fordyce | Director, Executive |
| Maha Katabi | Director |
| Scott Morrison | Director |
| Beth Seidenberg | Director |
| Kurt Von Emster | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
170 Harbor Way 3 Rd Floor
South San Francisco, CA, 94080
South San Francisco, CA, 94080